SEARCH:   Advanced

Blood, 1 March 2006, Vol. 107, No. 5, pp. 1970-1973. Prepublished online as a Blood First Edition Paper on November 10, 2005; DOI 10.1182/blood-2005-05-1958. This Article Full Text (PDF) All Versions of this Article: 2005-05-1958v1 107/5/1970    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Battiwalla, M. Articles by McCarthy, Jr., P. L Search for Related Content PubMed PubMed Citation Articles by Battiwalla, M. Articles by McCarthy, Jr., P. L Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted May 16, 2005 Accepted October 9, 2005 Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplants but does not impact chronic GVHD incidence Minoo Battiwalla*, Theresa Hahn, Marija Radovic, Hillary Roy, Afrin Wahab, Eileen Duman, Rajinder Bajwa, Swaminathan Padmanabhan, Joanne Becker, A J Barrett, and Philip L McCarthy, Jr. Departments of Medicine and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA * Corresponding author; email: minoo.battiwalla{at}roswellpark.org. TThe DR15 allele at the HLA DRB1 locus is a marker for immune-mediated bone marrow failure syndromes. We hypothesized that HLA DR15 plays a role in T-cell interactions with hematopoiesis and investigated the role of HLA DR15 on graft-versus-host disease (GVHD) and graft-versus-leukemia effects in HLA-matched allogeneic blood or marrow transplants (BMT) performed for myeloid malignancies. We performed a retrospective analysis of 119 consecutive related and 48 consecutive unrelated allogeneic BMTs for myeloid malignancies treated between 1991 and 2005 to investigate the influence of HLA DR15 on overall survival (OS), progression-free survival (PFS) and incidence of grade II-IV acute GVHD. HLA DR15 was determined by either molecular (n=108) or serologic (n=59) methods. The incidence of HLA DR15 was similar to the general Caucasian population (35/167=21%). There were no significant differences in transplant characteristics between the HLA DR15 positive and negative groups. There was no significant difference in chronic GVHD, OS or PFS between the HLA DR15 positive vs. negative groups in any disease or donor relation subgroups. The HLA DR15 positive group experienced a significantly lower incidence of acute GVHD grade II-IV: 23% vs. 42%, p=0.041. These results suggest that HLA DR15 reduces the risk of acute GVHD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Gupta, C. Aggarwal, P. L. McCarthy, S. Padmanabhan, M. Battiwalla, and T. E. Hahn Influence of Human Leukocyte Antigen Haplotypes on Acute Graft Versus Host Disease Incidence after Allogeneic Hematopoietic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 2887 - 2887. [Abstract] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020